Latest filing published 13 Apr 2022 for Graphite Bio, Inc., €18k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Phil Gutry: trading record in brief
Phil Gutry discloses dealings in LENZ Therapeutics, Inc. to SEC (Form 4). We count 4 filings; the first trade dates from 15 January 2021 and the latest from 11 April 2022.
Every open-market trade on record is a purchase: 1 purchase worth €18k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 option exercises. In 2022 alone, the filings show 1 purchase and no sales.
On 13 April 2022 came the latest disclosure, an open-market purchase for €18k in LENZ Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 38 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Phil Gutry
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$4.0145.0% of flowCommon StockSEC:0001209191-22-024362:0Canonical exit: 10 Jul 2022 (T+90)
- 91,406 shares@ US$0.3055.0% of flowCommon StockSEC:0000899243-21-027016:0
2 of 2 declarations
